Japan Agency for Medical Research and Development (AMED)
National Cancer Center Japan (NCC)
MEXT | Japan Society for the Promotion of Science (JSPS)
History
ARTICLE ABSTRACT
The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in constructing subtype-specific immune tumor microenvironments. These classifications of NSCLC based on TIL status are useful for developing personalized immune therapies for NSCLC.